{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=24",
    "query": {
      "condition": "Genetic Change",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 1795,
    "total_pages": 180,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T18:23:17.309Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03544983",
      "title": "Genetic Education in BRCA Families",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "BRCA1 Mutation",
        "BRCA2 Mutation"
      ],
      "interventions": [
        {
          "name": "Web + Streamlined Telephone Genetic Information",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 240,
      "start_date": "2020-05-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-11-13T18:23:17.309Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Danville, Pennsylvania",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Danville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03544983"
    },
    {
      "nct_id": "NCT03994796",
      "title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CDK Gene Mutation",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Malignant Solid Neoplasm",
        "NTRK Family Gene Mutation",
        "PI3K Gene Mutation",
        "ROS1 Gene Mutation",
        "KRAS G12C Mutation"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "PI3K Inhibitor paxalisib",
          "type": "DRUG"
        },
        {
          "name": "Entrectinib",
          "type": "DRUG"
        },
        {
          "name": "Adagrasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-10-17",
      "completion_date": "2028-06",
      "has_results": true,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-13T18:23:17.309Z",
      "location_count": 435,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03994796"
    },
    {
      "nct_id": "NCT00655161",
      "title": "A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "GI-4000",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlobeImmune",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2008-04",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2014-01-29",
      "last_synced_at": "2026-11-13T18:23:17.309Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00655161"
    },
    {
      "nct_id": "NCT01531673",
      "title": "Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "VX-661",
          "type": "DRUG"
        },
        {
          "name": "Ivacaftor",
          "type": "DRUG"
        },
        {
          "name": "Placebo matched to VX-661",
          "type": "DRUG"
        },
        {
          "name": "Placebo matched to ivacaftor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2012-02",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-13",
      "last_synced_at": "2026-11-13T18:23:17.309Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01531673"
    },
    {
      "nct_id": "NCT07361562",
      "title": "A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor, Adult",
        "ERBB2 Altered Breast Cancer",
        "ERBB2 Gene Amplification",
        "HER2 Overexpression",
        "Non-Small Cell Lung Cancer",
        "HER2"
      ],
      "interventions": [
        {
          "name": "CGT4255",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cogent Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-12-30",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-13T18:23:17.309Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07361562"
    },
    {
      "nct_id": "NCT06706388",
      "title": "Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dentatorubral-Pallidoluysian Atrophy"
      ],
      "interventions": [
        {
          "name": "nL-ATN1-002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "n-Lorem Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "17 Years to 17 Years · Male only"
      },
      "enrollment_count": 1,
      "start_date": "2024-02-21",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-11-13T18:23:17.309Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06706388"
    },
    {
      "nct_id": "NCT02859727",
      "title": "Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Activated PI3Kdelta Syndrome (APDS); PASLI Disease"
      ],
      "interventions": [
        {
          "name": "CDZ173",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 37,
      "start_date": "2016-09-08",
      "completion_date": "2025-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-11-13T18:23:17.309Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859727"
    },
    {
      "nct_id": "NCT05241873",
      "title": "(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Neoplasm Malignant",
        "Carcinoma, Non-Small-Cell Lung",
        "Respiratory Tract Neoplasms",
        "Neoplasms",
        "Neoplasms by Site",
        "Lung Diseases",
        "Respiratory Tract Disease",
        "Carcinoma, Bronchogenic",
        "Bronchial Neoplasms",
        "Adenocarcinoma",
        "Carcinoma",
        "Neoplasms by Histologic Type",
        "EGFR Exon 20 Mutation",
        "EGFR Exon 20 Insertion Mutation",
        "EGFR Activating Mutation",
        "Antineoplastic Agents",
        "Metastatic Lung Cancer",
        "Brain Metastases",
        "EGFR-mutated NSCLC",
        "EGFR Atypical Mutations, Including G719X and L861Q"
      ],
      "interventions": [
        {
          "name": "BLU-451",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blueprint Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2022-03-04",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-11-13T18:23:17.309Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05241873"
    },
    {
      "nct_id": "NCT02947386",
      "title": "Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "EGFR Gene Mutation",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Stage IIIA Non-Small Cell Lung Cancer",
        "Stage IIIB Non-Small Cell Lung Cancer",
        "Stage IV Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nimotuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2017-06-29",
      "completion_date": "2022-09-08",
      "has_results": false,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-11-13T18:23:17.309Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02947386"
    },
    {
      "nct_id": "NCT01760005",
      "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimers Disease",
        "Dementia",
        "Alzheimers Disease, Familial"
      ],
      "interventions": [
        {
          "name": "Gantenerumab",
          "type": "DRUG"
        },
        {
          "name": "Solanezumab",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo (Gantenerumab)",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo (Solanezumab)",
          "type": "DRUG"
        },
        {
          "name": "E2814",
          "type": "DRUG"
        },
        {
          "name": "Lecanemab",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo (E2814)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 490,
      "start_date": "2012-12",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-11-13T18:23:17.309Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01760005"
    }
  ]
}